இந்தியாவில் GLP-1 சிகிச்சைக்கு யார் தகுதி?

Type 2 diabetes GLP-1 therapy qualify who?

RSSDI clinical practice lifestyle, metformin glycaemic target achieve fail—typically HbA1c 7–7.5% above despite optimised care—GLP-1 RA important option position. Established cardiovascular disease, heart failure, chronic kidney disease, obesity, sulfonylurea hypoglycaemia risk patient particularly favour. Diabetes indication single BMI cut-off not; lean Indian type 2 diabetes patient overall cardiovascular, renal risk profile GLP-1 RA receive. Age, kidney function, concurrent medication selection influence. Type 1 diabetes, gestational diabetes specialist input without, diabetic ketoacidosis not indicated. Diabetologist/endocrinologist HbA1c trend, fasting/post-meal glucose, complication screening before class recommend. CDSCO-approved product Schedule H prescription clinical criteria clearly meet regardless.

India obesity GLP-1 criteria?

Obesity pharmacotherapy ICMR national guideline, South Asia adapted international protocol adult without comorbidity BMI ≥27.5 kg/m² medication consider threshold often. Comorbidity present BMI ≥25 kg/m². Western obesity guideline BMI ≥30 below sit—Indian lower body weight insulin resistance, fatty liver, cardiovascular risk develop. Waist circumference—South Asian men 90 cm+, women 80 cm+—BMI clinical assessment supplement. Pharmacotherapy never first-line; structured lifestyle intervention 3–6 month follow. Doctor motivation, mental health, eating disorder history, long-term therapy afford assess before prescribe. Metabolic indication without cosmetic motivation appropriate prescribing not. BMI threshold meet structured lifestyle attempt not doctor pharmacotherapy defer dietitian refer first.

Thin-fat phenotype

South Asian common pattern: apparently normal BMI high visceral fat, low muscle—early metabolic disease associate.

Indian BMI threshold Western guideline differ why?

Asian Indian phenotype (Joshi et al. literature) higher visceral adiposity, greater insulin resistance, earlier type 2 diabetes onset same BMI Caucasian compare. Chennai BMI 26 waist 92 cm European BMI 28 compare more metabolic risk. RSSDI, ICMR guideline incorporate. Clinical judgement essential: BMI 27 no comorbidity marathon vegetarian differently manage sedentary executive BMI 27 prediabetes, fatty liver. Genetic predisposition, family history, socioeconomic context population guideline fully capture individual decision factor. WHO Asian BMI cut-off expert consultation underpin; India-specific ICMR guidance most directly relevant patient document.

BMI threshold: Western vs India-aligned guidance

• Context: Pharmacotherapy without comorbidity — Western obesity cut-off: Often BMI ≥30 — India-aligned threshold: Often BMI ≥27.5 (ICMR)
• Context: Pharmacotherapy with comorbidity — Western obesity cut-off: Often BMI ≥27 — India-aligned threshold: Often BMI ≥25 with comorbidity
• Context: Waist circumference focus — Western obesity cut-off: Less emphasised — India-aligned threshold: Central obesity central to risk
• Context: Lifestyle trial first — Western obesity cut-off: Recommended — India-aligned threshold: Required 3–6 months (ICMR)
• Context: Type 2 diabetes indication — Western obesity cut-off: Glycaemic criteria — India-aligned threshold: RSSDI: after metformin if uncontrolled

Earlier GLP-1 consideration support common comorbidity (BMI ≥25)

• Comorbidity: Prediabetes / elevated HbA1c — Why it matters: Diabetes progression reduce; insulin sensitivity improve
• Comorbidity: Hypertension — Why it matters: Weight loss, glycaemic control blood pressure management support
• Comorbidity: Dyslipidaemia — Why it matters: GLP-1 RA triglyceride, weight-related lipid improve may
• Comorbidity: NAFLD / fatty liver — Why it matters: 5–10% weight loss hepatic steatosis reduce
• Comorbidity: Obstructive sleep apnoea — Why it matters: Weight reduction apnoea severity many patient improve
• Comorbidity: Established cardiovascular disease — Why it matters: RSSDI high-risk diabetes patient GLP-1 RA favour

GLP-1 therapy case strengthen comorbidity?

BMI beyond metabolic condition cluster weigh. Central obesity prediabetes, multiple agent hypertension, high triglyceride, ultrasound NAFLD, obstructive sleep apnoea lifestyle alone not suffice pharmacotherapy justification add. Insulin resistance PCOS endocrine discussion frequent prompt. Premature cardiovascular disease/diabetes family history borderline number risk framing strengthen. RSSDI cardiovascular risk integration diabetes heart disease patient treatment algorithm isolated mild obesity patient earlier GLP-1 RA receive may. Lab report, imaging summary self-report alone document. ICMR obesity chronic disease complication treat—not cosmetic issue emphasise.

Qualify not/specialist review need who?

Contraindication: pregnancy, breastfeeding; MTC/MEN2 personal/family history; severe prior pancreatitis. Severe gastroparesis, active IBD, frail elderly low BMI further weight loss harmful caution. Inadequately treated eating disorder psychiatric support before appetite-suppress medicine. Prescribed monitoring commit/sustained therapy afford unable alternative counsel. First-degree relative thyroid cancer careful endocrine evaluation. Kesho patient screen/eligibility determination not—full history, examination, investigation treating physician alone decide. CDSCO product label contraindication BMI regardless legally binding.